Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease

Gut

Volumn 61, Issue 4, 2012, Pages 501-506

  Zerbib, Frank ^a,b   Belhocine, Kafia ^c,d   Simon, Mireille ^a,b   Capdepont, Maylis ^a,b   Mion, François ^e,f   Des Varannes, Stanislas Bruley ^c,d   Galmiche, Jean Paul ^c,d  

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENDOSCOPY; FEMALE; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PH MEASUREMENT; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; DYSPEPSIA; ESOPHAGEAL PH MONITORING; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROGNOSIS; PROTON PUMP INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857798723     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300798     Document Type: Article

References (37)

1. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810. (Pubitemid 27240763)
2. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58:295-309.
3. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-64. (Pubitemid 39013424)
4. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastrooesophageal reflux disease: a double- blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73. (Pubitemid 27376366)
5. Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004;19(Suppl 1):28-34. (Pubitemid 38253489)
6. Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol 2010;105:2626-31.
7. Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther 2007;26:453-61. (Pubitemid 47063139)
8. Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008;27:473-82. (Pubitemid 351300853)
9. Aanen MC, Weusten BL, Numans ME, et al. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association. J Clin Gastroenterol 2008;42:441-7. (Pubitemid 351572258)
10. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9. (Pubitemid 27433659)
11. Wiener GJ, Richter JE, Copper JB, et al. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988;83:358-61.
12. Weusten BL, Roelofs JM, Akkermans LM, et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994;107:1741-5. (Pubitemid 24357628)
13. Taghavi SA, Ghasedi M, Saberi-Firoozi M, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005;54:1067-71. (Pubitemid 41025896)
14. Watson RG, Tham TC, Johnston BT, et al. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux-the "sensitive oesophagus". Gut 1997;40:587-90. (Pubitemid 27278323)
15. Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009;58:1185-91.
16. Shi G, Bruley des Varannes S, Scarpignato C, et al. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995;37:457-64.
17. Sifrim D, Castell D, Dent J, et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024-31. (Pubitemid 38824163)
18. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398-402. (Pubitemid 44476780)
19. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956-63. (Pubitemid 44337616)
20. Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut 2006;55:313-18. (Pubitemid 43268266)
21. Zerbib F, Duriez A, Roman S, et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008;57:156-60. (Pubitemid 351158039)
22. Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am J Gastroenterol 2008;103:1090-6. (Pubitemid 351677992)
23. Zerbib F, des Varannes SB, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005;22:1011-21. (Pubitemid 41634884)
24. Noh YW, Jung HK, Kim SE, et al. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil 2010;16:148-56.
25. Nastaskin I, Mehdikhani E, Conklin J, et al. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 2006;51:2113-20.
26. Broeders JA, Draaisma WA, Bredenoord AJ, et al. Impact of symptom-reflux association analysis on long-term outcome after Nissen fundoplication. Br J Surg 2011;98:247-54.
27. Slaughter JC, Goutte M, Rymer JA, et al. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2011;9:868-74.
28. Fletcher J, Derakhshan MH, Jones GR, et al. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut 2011;60:442-8.
29. Heading RC, Monnikes H, Tholen A, et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol 2011;11:52.
30. El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut 2007;56:749-55. (Pubitemid 46854185)
31. Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006;354:2340-8. (Pubitemid 43801279)
32. Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007;132:883-9. (Pubitemid 46440865)
33. Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006;130:639-49. (Pubitemid 43374513)
34. Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol 2011;9:824-33.
35. Wu JC, Lai LH, Chow DK, et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil 2011;23:155-60.
36. Dickman R, Boaz M, Aizic S, et al. Comparison of anxiety and depression in gastroesophageal reflux disease (GERD) patients who failed proton pump inhibitor (PPI) therapy versus those who fully responded to it. Gastroenterology 2011; 140:S-582.
37. Castell DO, Zerbib F, Bruley Des Varannes S, et al. Efficacy and tolerability of ADX10059, a mGluR5 negative allosteric modulator, as add on therapy to proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD). Gastroenterology 2011;140:S-577.